CTMX CytomX Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1501989 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-87.7%
TTM net income YoY-404.9%
TTM EPS YoY-329.6%
Revenue 3-yr CAGR-43.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-676.5%
Net margin-609.0%
FCF margin-363.6%
EBITDA margin—
Returns
ROE-43.6%
ROA-32.7%
ROIC (approx.)-46.3%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets21.9%
Debt / equity0.00x
Current ratio7.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $76.20M | $138.10M |
| R&D expense | $68.73M | $83.38M |
| SG&A expense | $29.84M | $29.73M |
| Operating income | -$22.36M | $25.00M |
| Pretax income | -$17.13M | $32.09M |
| Income tax | $238,000 | $224,000 |
| Net income | -$17.37M | $31.87M |
| EBITDA | -$21.16M | $26.59M |
| EPS (diluted) | — | — |
| Weighted avg. shares (diluted) | 137.94M | 84.75M |
| Balance sheet | ||
| Cash & equivalents | $12.67M | $38.05M |
| Short-term investments | $124.39M | $62.57M |
| Receivables | $2.01M | $3.10M |
| Current assets | $143.92M | $107.31M |
| PP&E, net | $1.30M | $2.47M |
| Goodwill | $949,000 | $949,000 |
| Total assets | $151.57M | $120.53M |
| Current liabilities | $46.62M | $85.77M |
| Total liabilities | $52.56M | $120.99M |
| Shareholders' equity | $99.01M | -$456,000 |
| Shares outstanding | 170.19M | 80.10M |
| Cash flow statement | ||
| Operating cash flow | -$75.59M | -$86.23M |
| Capital expenditure | $220,000 | $310,000 |
| Free cash flow | -$75.81M | -$86.54M |
| Investing cash flow | -$59.74M | $99.70M |
| Financing cash flow | $110.45M | $7.52M |
| Depreciation & amortization | $1.20M | $1.60M |
| Stock-based compensation | $6.30M | $7.67M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.